Pulmonary Arterial Hypertension Market Outlook 2032 | Pfizer, Eli Lilly and Company, United Therapeutics Corporation, Gilead Sciences, GSK, ICOS Corporation, Actelion Pharmaceuticals, Nippon Shinyaku

Pulmonary Arterial Hypertension Market

According to DelveInsight, the Pulmonary Arterial Hypertension (PAH) market is poised for growth in the upcoming years. This is attributed to the expanding patient population in the 7MM (Seven Major Markets), the substantial research and development (R&D) efforts by pharmaceutical firms, as well as the approval and launch of pipeline therapies.

DelveInsight’s “Pulmonary Arterial Hypertension Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Pulmonary Arterial Hypertension market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan).

The Pulmonary Arterial Hypertension market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Recent advancement in the Pulmonary Arterial Hypertension Market:

• Merck (known as MSD outside of the United States and Canada) has achieved a significant milestone. The U.S. Food and Drug Administration (FDA) has approved sotatercept-csrk, branded as WINREVAIR™, for the treatment of adults with PAH (World Health Organization [WHO] Group 1). This approval marks a breakthrough, as WINREVAIR is the first FDA-approved activin signaling inhibitor therapy for PAH. It represents a new class of therapy that works by improving the balance between pro- and anti-proliferative signaling to regulate vascular cell proliferation underlying PAH.

Pulmonary Arterial Hypertension Overview

Pulmonary Arterial Hypertension is a serious condition characterized by high blood pressure in the arteries that supply blood to the lungs. This increased pressure in the pulmonary arteries can lead to various symptoms and complications.

Pulmonary Arterial Hypertension Causes: PAH can be idiopathic (of unknown cause) or associated with other conditions such as connective tissue diseases, congenital heart defects, liver disease, HIV infection, and certain drugs and toxins.

Pulmonary Arterial Hypertension Signs and Symptoms: Symptoms of PAH include shortness of breath, fatigue, chest pain, fainting, swelling in the ankles and legs, bluish lips or skin (cyanosis), and a rapid heartbeat. These symptoms can worsen over time and significantly impact a person’s quality of life.

Pulmonary Arterial Hypertension Diagnosis: Diagnosis of PAH typically involves a thorough medical history, physical examination, and various tests such as echocardiography, electrocardiography (ECG), chest X-ray, pulmonary function tests, and right heart catheterization. These tests help assess the severity of the condition and rule out other potential causes of symptoms.

Pulmonary Arterial Hypertension Treatment Options: Treatment for PAH aims to relieve symptoms, improve quality of life, and slow disease progression. Several treatment options are available in the market, including:

• Medications: Various medications are used to treat PAH, including vasodilators, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogs. These medications help relax blood vessels, reduce blood pressure, and improve blood flow to the lungs.
• Oxygen Therapy: Supplemental oxygen therapy may be prescribed to improve oxygen levels in the blood and alleviate symptoms such as shortness of breath.
• Pulmonary Rehabilitation: Pulmonary rehabilitation programs may be recommended to help improve exercise capacity, reduce symptoms, and enhance overall well-being.
• Surgical Procedures: In some cases, surgical procedures such as atrial septostomy or lung transplantation may be considered for patients with severe PAH who do not respond to other treatments.
• Lifestyle Changes: Lifestyle modifications such as regular exercise, maintaining a healthy diet, avoiding smoking, and managing underlying conditions (such as heart or lung diseases) can also help manage PAH symptoms and improve overall health.

Pulmonary Arterial Hypertension Market Key Facts

• The Pulmonary Arterial Hypertension market size in the 7MM was ~USD 4,871.0 million in 2021, which is further expected to increase by 2032.
• The market size in the 7MM will increase at a CAGR of 3.6% due to increasing awareness of the disease and the launch of emerging therapies. 
• Among the 7MM countries, the US accounted for the highest market size of Pulmonary Arterial Hypertension, with approximately USD 3,848.1 million in 2021.
• The total Pulmonary Arterial Hypertension prevalent cases in the 7MM were estimated to be approximately 87,000+ cases in 2021, which are expected to increase by 2032.
• According to DelveInsight estimates, in 2021, the total diagnosed prevalent cases of Pulmonary Arterial Hypertension were estimated to be approximately 52,600+ in the 7MM.
• Among the 7MM, the United States accounted for nearly 58% of the total diagnosed prevalent cases of Pulmonary Arterial Hypertension in the 7MM in the year 2021.
• Some of the key players in the Pulmonary Arterial Hypertension Market include Pfizer, Eli Lilly and Company, United Therapeutics Corporation, Gilead Sciences, GSK, ICOS Corporation, Actelion Pharmaceuticals, Nippon Shinyaku, Bayer Group, Actelion Pharmaceuticals, Co Therix, Kaken Pharmaceutical, Sanofi-Aventis, Toray, Acceleron Pharma Inc., Altavant Sciences, Aerovate Therapeutics, Respira Therapeutics, Gossamer Bio Inc., Merck Sharp & Dohme Corp., Insmed Incorporated, Pharmaosa Biopharma Inc., Bial (Portela C S.A.), Liquida Technologies, Inc., Cereno Scientific AB, and others.
• According to DelveInsight, the overall dynamics of the Pulmonary Arterial Hypertension market are anticipated to change in the coming years owing to the expected launch of emerging therapies.

Pulmonary Arterial Hypertension Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Pulmonary Arterial Hypertension market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Pulmonary Arterial Hypertension market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Pulmonary Arterial Hypertension Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Pulmonary Arterial Hypertension Epidemiology, Segmented by –

• Total Prevalent Patient Population of Pulmonary Arterial Hypertension
• Sub-type Specific Prevalence of Pulmonary Arterial Hypertension
• Gender-specific Prevalence of Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pulmonary Arterial Hypertension market or expected to get launched during the study period. The analysis covers the Pulmonary Arterial Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Pulmonary Arterial Hypertension Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How Pulmonary Arterial Hypertension Market Will Evolve by 2032 @ https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pah-market

Pulmonary Arterial Hypertension Therapeutics Analysis

The rise in the prevalence of this condition and the approval of upcoming therapies are poised to have a favorable effect on the market in the foreseeable future. While existing FDA-approved medications enhance quality of life and hemodynamic metrics, none provide a definitive cure for Pulmonary Arterial Hypertension. Extensive research endeavors have spurred the development of novel therapeutic strategies within the realm of Pulmonary Arterial Hypertension.

Some of the Leading Companies in the Pulmonary Arterial Hypertension Therapeutics Market Include 

• Merck
• United Therapeutics
• Liquida Technologies
• Tenax Therapeutics
• Respira Therapeutics
• Gossamer Bio
• Pharmosa Biopharma
• Aerovate Therapeutics
• Insmed
• Novartis
• Cumberland Pharmaceuticals
• Enzyvant Therapeutics
• AstraZeneca
• Cereno Scientific
• PhaseBio Pharmaceutical
• And Many Others

 Pulmonary Arterial Hypertension Drugs Covered in the Report Include: 

• Sotatercept (MK-7962) (Merck)
• Ralinepag (United Therapeutics)
• RT234 (vardenafil inhalation powder) (Respira Therapeutics)
• Seralutinib (GB002) (Gossamer Bio)
• YUTREPIA (inhaled dry powder formulation of treprostinil) (Liquidia Technologies)
• TNX-201 (Tenax Therapeutics)
• CS1 (CerenoScientific),
• RVT-1201 (Altavant Sciences)
• Bardoxolone methyl (Reata Pharmaceuticals, Inc.)
• PB1046 Injection (PhaseBio Pharmaceuticals Inc.)
• CXA-10 (Complexa, Inc.)
• And others.

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More: https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pah-market

Table of Content

1. Key Insights

2. Executive Summary 

3. Pulmonary Arterial Hypertension Competitive Intelligence Analysis

4. Pulmonary Arterial Hypertension Market Overview at a Glance

5. Pulmonary Arterial Hypertension Disease Background and Overview

6. Pulmonary Arterial Hypertension Patient Journey

7. Pulmonary Arterial Hypertension Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Pulmonary Arterial Hypertension Treatment Algorithm, Current Treatment, and Medical Practices

9. Pulmonary Arterial Hypertension Unmet Needs

10. Key Endpoints of Pulmonary Arterial Hypertension Treatment

11. Pulmonary Arterial Hypertension Marketed Products

12. Pulmonary Arterial Hypertension Emerging Drugs and Latest Therapeutic Advances

13. Pulmonary Arterial Hypertension Seven Major Market Analysis

14. Attribute Analysis

15. Pulmonary Arterial Hypertension Market Outlook (In US, EU5, and Japan)

16. Pulmonary Arterial Hypertension Access and Reimbursement Overview

17. KOL Views on the Pulmonary Arterial Hypertension Market

18. Pulmonary Arterial Hypertension Market Drivers

19. Pulmonary Arterial Hypertension Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Other Trending Healthcare Reports By DelveInsight

Pulmonary Arterial Hypertension Pipeline Insight

Pulmonary Arterial Hypertension – Pipeline Insight, 2024” report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in the Pulmonary Arterial Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/